Skip to content
Menu

Scholar Rock Holding Corporation SRRK

Full chart Compare
Set alert

Price alert · SRRK

All alert types
48.13 USD -2.24 (-4.45%)

Regular-session close

48.13 0.00 0.00%

After hours · Nov 20, 4:52 PM ET

47.94 Day range 52.17
38.02 52-week range 61.76
YTD
+9.26%
1 year
+26.59%

5D +5.06 (+11.72%)

4550MonTueWedThuFri48.25
Market cap
5.87B
Revenue (ttm)
570.00K
EPS (ttm)
-3.23
Shares out
122.00M
Forward P/E
-19.61
YTD return
+9.26%
1-year return
+26.59%
50-day average
45.43
200-day average
48.25
Enterprise value
5.93B
Volume
2.08M
Avg volume
1.85M
Open
49.63
Previous close
50.37
Day's range
47.94 – 52.17
52-week range
38.02 – 61.76
Beta
0.79
Analysts
Strong Buy
Price target
70.06 (+45.6%)
Earnings date
Mar 2, 2027

Key statistics

Price / sales
10301.89
Price / book
34.80
Free cash flow
-168.63M
Total cash
413.60M
Total debt
202.99M
Return on equity
-199.97%
Short % of float
24.02%

Fundamental scorecard

3 of 25 checks passed on SRRK’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SRRK Revenue — quarterly 570.00K
SRRK Net income — quarterly -107.24M
SRRK EPS — quarterly -0.81

Earnings

SRRK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 2, 2027Dec 30, 2026-0.49496———
Nov 10, 2026Sep 30, 2026-0.84718-0.81+0.04+4.39%
Aug 6, 2026Jun 30, 2026-0.8405-0.840.00+0.06%
May 7, 2026Mar 31, 2026-0.82-0.83-0.01-1.22%
Mar 3, 2026Dec 31, 2025-0.88252-0.880.00+0.29%
Nov 14, 2025Sep 30, 2025-0.83517-0.90-0.06-7.76%

Upgrades / downgrades

SRRK analyst upgrades and downgrades
DateFirmActionFromTo
Nov 12, 2026Wolfe ResearchdownOutperformPeer Perform
Sep 24, 2026Truist SecuritiesmainBuyBuy
Sep 21, 2026JP MorganmainOverweightOverweight
Sep 15, 2026Evercore ISI GroupmainOutperformOutperform
Sep 15, 2026Piper SandlermainOverweightOverweight
Sep 15, 2026JefferiesmainBuyBuy

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SRRK — it syncs with the Stock Master app.

Insider holders

SRRK insider holders
InsiderRelationLatest transactionDateShares held
AKKARAJU SRINIVASDirectorPurchaseOct 25, 20260
BACKSTROM JAY TChief Executive OfficerStock Award(Grant)Mar 9, 2025425,561
BUROW KRISTINA MDirectorSaleJun 30, 20262,460,370
HALLAL DAVID LChief Executive OfficerStock GiftSep 20, 20261,844,030
HO JUNLINGeneral CounselSaleFeb 16, 2026241,545
INVUS GLOBAL MANAGEMENT, LLCBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityDec 10, 20250

Institution ownership

SRRK institution ownership
Holder% heldSharesValueReported
FMR, LLC14.92%18,207,328876.32MSep 29, 2026
Blackrock Inc.7.83%9,558,524460.05MSep 29, 2026
Siren, L.L.C.7.68%9,375,013451.22MSep 29, 2026
Wellington Management Group, LLP7.14%8,708,303419.13MSep 29, 2026
Samsara BioCapital, LLC5.65%6,897,652331.98MSep 29, 2026
Orbis Allan Gray Ltd4.98%6,075,392292.41MSep 29, 2026

Fund ownership

SRRK fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund3.72%4,533,645218.20MSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.16%3,859,866185.78MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.81%3,427,521164.97MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.37%2,893,020139.24MSep 29, 2026
MFS Series Trust IV-MFS Mid Cap Growth Fund2.10%2,557,599123.10MAug 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.88%2,299,437110.67MJun 29, 2026